Fintel reports that on January 8, 2025, BTIG downgraded their outlook for Inari Medical (NasdaqGS:NARI) from Buy to Neutral.

BTIG analyst Ryan Zimmerman maintained a Buy rating on Stryker (SYK – Research Report) yesterday and set a price target of $394.00. The ...

Shares of Palo Alto Networks (NASDAQ:PANW) fell more than 2% in premarket trading Wednesday after analysts at BTIG and ...

Here are four large-cap value stocks that growth and income investors may want to consider now. History suggests they will ...

Analyst Mark Massaro of BTIG reiterated a Buy rating on Castle Biosciences (CSTL – Research Report), reducing the price target to $40.00.Stay ...

Last week, BTIG analyst Jake Fuller reiterated a Buy rating on Uber Technologies (UBER) stock with a price target of $90. The analyst remains bullish on the ride-hailing company but expects its Q4 ...

BTIG is growing its transition management business and hired a senior executive to help boost business. The firm has hired Daniel Howell as a director who will be based in New York. His job is simple ...

BTIG analyst Jake Fuller says that while Uber‘s (UBER) commentary on its U.S. rideshare business “felt constructive” at intra-quarter appearances, the firm’s receipt data was “more ...

The S&P 500's rally of 1.8% over just the last two sessions is nice, "but not a game changer yet," according to BTIG's technical guru, Jonathan Krinsky. The chart he provides, below, shows the stock ...

BTIG's Krinsky noted that while equity markets in the first half of 2024 were fueled mostly by the surge in mega-cap names ...

BTIG analyst Marie Thibault raised the firm’s price target on Boston Scientific (BSX) to $101 from $97 and keeps a Buy rating ...

According to a BTIG strategist, the rally in the index was rejected from the previous support trendline and even though there are still four days left for the Santa Claus rally to deliver gains, there ...